1345 (1345) Fair Value & Analysis

Healthcare · Market cap HK$2.7B

1 1345 1345 · HK

PriceHK$2.30

Fair ValueHK$2.44

Upside+6.1%

Quality72/100

Evidence: High Range HK$1.80 – HK$3.03

Fair value as of: Jul 2, 2026

From 22 valuation models · updated today

Share price +2.9% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$1.64 – HK$2.31 · fair‑value band HK$1.80 – HK$3.03 · the HK$2.30 price screens below the HK$2.44 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1345 (1345) currently trades at HK$2.30, while our model-based Fair Value estimate is HK$2.44 — implying the stock looks roughly 6.1% undervalued today. We read business quality at 72/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 1345 generated revenue of HK$1.3B at a net margin of 8.9%. Revenue declined 10.8% year over year. It earns a return on equity of 9.7%. The balance sheet holds a net cash position of HK$69.3M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.3B

Revenue growth (YoY) -10.8%

Net margin 8.9%

Return on equity 9.7%

Free cash flow HK$189M FY2025

P/E ratio 19.2

More key figures

Operating margin 11.4%

EPS (TTM) HK$0.0400

Dividend yield 4.7%

EPS growth (YoY) +20.2%

Net cash HK$69.3M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1345 reported revenue of HK$1.3B in FY2025 versus HK$1.4B in FY2021, a compound −2.7%/yr. Reported net income was HK$114M in FY2025, compounding −5.4%/yr from FY2021.

Revenue −2.7%/yr

FY21 HK$1.4B

FY22 HK$1.6B

FY23 HK$1.6B

FY24 HK$1.5B

FY25 HK$1.3B

Net income −5.4%/yr

FY21 HK$143M

FY22 HK$235M

FY23 HK$146M

FY24 HK$152M

FY25 HK$114M

Is 1345 fairly valued? → Check now

Similar stocks

6 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
JD Health International Inc JDHIY	$5.33	$7.09	+33%
Alibaba Health Information Technology Limited ALBBY	$8.56	$6.91	-19%
0241 0241	HK$3.08	HK$2.04	-34%
Raia Drogasil S.A RADL3	R$16.79	R$20.39	+21%
Yifeng Pharmacy Chain Co 603939	¥19.75	¥29.07	+47%
Clicks Group CLCGY	$28.55	$41.54	+45%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1345 (1345) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$2.44 versus a price of HK$2.30 — about +6% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 1345?

Our model-based fair value for 1345 is HK$2.44 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$2.30.

What is the quality score of 1345?

1345 has a Quality Score of 72/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1345 (1345)?

1345 reported trailing-twelve-month revenue of about HK$1.3B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1345?

The net profit margin of 1345 is about 8.9%, meaning it keeps roughly 8.9% of revenue as net income. Based on the latest reported figures.

Does 1345 pay a dividend?

1345 currently shows a dividend yield of about 4.65% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.